2-[3-(fluoromethoxy)phenyl]-N-[6-[4-[5-[(2-pyridin-2-ylacetyl)amino]-1,3,4-thiadiazol-2-yl]butyl]pyridazin-3-yl]acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[3-(fluoromethoxy)phenyl]-N-[6-[4-[5-[(2-pyridin-2-ylacetyl)amino]-1,3,4-thiadiazol-2-yl]butyl]pyridazin-3-yl]acetamide
• 化学式: C₂₆H₂₆FN₇O₃S
• 分子量: 535.6
• InChiKey: KESWRXJFPSIKJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  38
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  160
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• HETEROCYCLIC GLUTAMINASE INHIBITORS
  申请人：CALITHERA BIOSCIENCES, INC.

  公开号：US20140194421A1

  公开（公告）日：2014-07-10

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.

  本发明涉及新型杂环化合物及其制药制剂。本发明还涉及使用所述新型杂环化合物的方法进行治疗。
• Treatment of Lung Cancer with Inhibitors of Glutaminase
  申请人：Calithera Biosciences, Inc.

  公开号：US20160287585A1

  公开（公告）日：2016-10-06

  The invention relates to methods of treating lung cancer using glutaminase inhibitors. In particular, results demonstrate that lung cancers characterized by an EGFR or KRAS mutation are treated by glutaminase inhibitors.
• [EN] COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS<br/>[FR] TRAITEMENT COMBINÉ AVEC DES INHIBITEURS DE GLUTAMINASE
  申请人：CALITHERA BIOSCIENCES INC

  公开号：WO2015192014A1

  公开（公告）日：2015-12-17

  The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an anticancer agent such as an enzyme inhibitor (such as a kinase inhibitor), a mitotic inhibitor, a DNA-modifying agent, or a cytidine analog. The invention further relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases that are resistant to one or more anticancer agents.